Search

Your search keyword '"Kataja, Vesa"' showing total 14 results

Search Constraints

Start Over You searched for: Author "Kataja, Vesa" Remove constraint Author: "Kataja, Vesa" Journal journal of clinical oncology Remove constraint Journal: journal of clinical oncology
14 results on '"Kataja, Vesa"'

Search Results

1. Digital patient-reported outcomes and serological response to SARS-COV-2 vaccines in patients with cancer.

2. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial

3. Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.

6. Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.

7. Biweekly cabazitaxel as a safe treatment option for metastatic castration resistant prostate cancer (mCRPC) patients post-docetaxel: Final analysis of Prosty II trial.

10. CHEK2*1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer–Specific Death, and Increased Risk of a Second Breast Cancer

11. First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.

12. Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial.

13. Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

14. Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

Catalog

Books, media, physical & digital resources